Arribas J - Search Results

1

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J. Serra V, et al. Among authors: arribas j. J Clin Invest. 2013 Jun;123(6):2551-63. doi: 10.1172/JCI66343. Epub 2013 May 1. J Clin Invest. 2013. PMID: 23635776 Free PMC article.

2

Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing.

Merlos-Suárez A, Fernández-Larrea J, Reddy P, Baselga J, Arribas J. Merlos-Suárez A, et al. Among authors: arribas j. J Biol Chem. 1998 Sep 18;273(38):24955-62. doi: 10.1074/jbc.273.38.24955. J Biol Chem. 1998. PMID: 9733803 Free article.

3

The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP).

Ureña JM, Merlos-Suárez A, Baselga J, Arribas J. Ureña JM, et al. Among authors: arribas j. J Cell Sci. 1999 Mar;112 ( Pt 6):773-84. doi: 10.1242/jcs.112.6.773. J Cell Sci. 1999. PMID: 10036228

4

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Codony-Servat J, et al. Among authors: arribas j. Cancer Res. 1999 Mar 15;59(6):1196-201. Cancer Res. 1999. PMID: 10096547

5

A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface.

Fernández-Larrea J, Merlos-Suárez A, Ureña JM, Baselga J, Arribas J. Fernández-Larrea J, et al. Among authors: arribas j. Mol Cell. 1999 Apr;3(4):423-33. doi: 10.1016/s1097-2765(00)80470-0. Mol Cell. 1999. PMID: 10230395 Free article.

6

The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein.

Borrell-Pagès M, Fernández-Larrea J, Borroto A, Rojo F, Baselga J, Arribas J. Borrell-Pagès M, et al. Among authors: arribas j. Mol Biol Cell. 2000 Dec;11(12):4217-25. doi: 10.1091/mbc.11.12.4217. Mol Biol Cell. 2000. PMID: 11102519 Free PMC article.

7

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Molina MA, et al. Among authors: arribas j. Cancer Res. 2001 Jun 15;61(12):4744-9. Cancer Res. 2001. PMID: 11406546

8

Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme.

Merlos-Suárez A, Ruiz-Paz S, Baselga J, Arribas J. Merlos-Suárez A, et al. Among authors: arribas j. J Biol Chem. 2001 Dec 21;276(51):48510-7. doi: 10.1074/jbc.M103488200. Epub 2001 Oct 12. J Biol Chem. 2001. PMID: 11600492 Free article.

9

Mechanism of action of trastuzumab and scientific update.

Baselga J, Albanell J, Molina MA, Arribas J. Baselga J, et al. Among authors: arribas j. Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11. doi: 10.1016/s0093-7754(01)90276-3. Semin Oncol. 2001. PMID: 11706390 Review.

10

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. Anido J, et al. Among authors: arribas j. Clin Cancer Res. 2003 Apr;9(4):1274-83. Clin Cancer Res. 2003. PMID: 12684395

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

742 results

Search Page